The Medical Letter on Drugs and Therapeutics
Nebulized Glycopyrrolate (Lonhala Magnair) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, handheld, electronic nebulizer. Glycopyrrolate is also available as a dry powder inhaler, both alone (Seebri Neohaler) and in combination with indacaterol (Utibron Neohaler), and as a metered-dose inhaler in combination with formoterol (Bevespi Aerosphere).1 Lonhala Magnair is the first nebulized LAMA to become available in the US.

CLINICAL STUDIES — The efficacy of nebulized glycopyrrolate was evaluated in two 12-week trials (GOLDEN 3 and 4) in 1294 patients with moderate to very severe COPD who were randomized to receive glycopyrrolate 25 mcg or 50 mcg or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nebulized Glycopyrrolate (Lonhala Magnair) for COPD
Article code: 1545d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian